It has been reported that higher levels of RSS1 and BOP1 are observed in 14% and 8%, respectively, of prostate adenocarcinomas and that higher levels of RRS1 mRNA correlate with shorter progression-free periods. The gene discussed is BOP1; the disease is prostate adenocarcinoma.